Participants
This study was conducted from April 2018 until November 2019 during which 222 women were included into the PROVE biobank. Fifty-one women did not have cognitive function assessments as they were included in the biobank for other sub-studies. One hundred seventy-one women had assessments for cognitive function. Eleven were excluded due to language barriers. Seven women from the group of pre-eclampsia without severe features were excluded as they developed renal impairment and/or HELLP. Of the 153 included in the study, 61 had eclampsia, 28 had pre-eclampsia complicated by pulmonary oedema, 38 had pre-eclampsia without severe complications and 26 had normotensive pregnancies (Figure 1). The majority had both subjective (n=140) and objective (n=139) assessments performed. Both CFQ and MoCA tests were administered as close to discharge as possible and none of the participants were treated with magnesium sulphate at time of testing.